‘In It For The Long Haul‘ – Celltrion Remains Committed To US Biosimilars
Chief Commercial Officer Talks Humira Competition And Future Launch Plans
Almost a year after launching Celltrion’s Yuflyma rival to Humira in the US, Tom Nusbickel, chief commercial officer of Celltrion USA, reflects on experiences in the market so far and key launches on the horizon, in an exclusive interview with Generics Bulletin.
